A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

Materials and methods

Raw materials. Pellets were prepared from a binary mixture of a drug substance (DS) and microcrystalline cellulose (MCC). The DS, an antidepressant supplied by Pierre Fabre Research Institute, is highly soluble in water (1250 g/L, median drug particle size: 14 μm, dispersion: 1.5). MCC (Avicel PH101, median drug particle size: 50 μm, FMC Biopolymer, Philadelphia) is insoluble in water. The ratio of DS to MCC was 36:64 (% w/w) in this study. Purified water was used at different concentrations as liquid binder.


Figure 1: Factors and responses of the experimental design.
Experimental design. A response surface design of experiments was built with Design Expert software version 7.0.0 (Stat-Ease, Minneapolis). The mathematical model targeted for each response studied was a quadratic model with firstorder interactions. The authors studied three factors: percent water quantity (A), extrusion speed (B), and extrusion system (C). To analyze the results, the extruder system was included as a qualitative factor, whereas water quantity and extrusion speed were continuous factors.


Figure 2: Pellet-manufacturing flow chart.
The levels of the continuous factors were determined by preliminary trials. Five levels of water quantity were tested in the range of 22.5–32.5%. According to preliminary tests, it was impossible to create pellets with water quantities beyond these limits. Three levels of extrusion speed were tested in the range of 20–60 rpm. Radial, dome, and axial extrusion systems were tested. All other experimental conditions were kept constant. Two replicates of the median conditions (i.e., 27.5% water and 40 rpm extrusion speed) were run for each extruder type. The experimental design comprised 27 experiments. All factor-level combinations were carried out in a randomized order. Figure 1 summarizes factors and responses selected for the design of experiments.


Figure 3: Extrusion of the wet mass in radial, dome, and axial extrusion systems.
Pellet preparation. MCC pellets containing 36% DS were made by extrusion–spheronization. Dry blending of MCC and DS was a common step to all the batches. After blending, 550 g of dry mix were sampled for subsequent steps. Wetting and granulation were performed in an Aoustin kneader (RPA Process, Nanterre, France). The wet mass obtained was extruded in an MG-55 extruder (FujiPaudal, Osaka). The extrudates were then spheronized in a Multi Bowl Spheronizer 250 (Caleva, Sturminster Newton, UK) and the pellets obtained were dried in a UT6120 drying oven (Heraeus, Hanau, Germany). Process conditions were fixed according to the flow chart shown in Figure 2. The authors used the MG-55 single-screw extruder to test the three extrusion configurations (see Figure 3). The axial system incorporated a flat end-plate screen perpendicular to the end of the screw. The dome system had an arch-shaped endplate screen at the end of the screw. The extrudates were ejected out of the screens at the end of the axial and dome extruders. In the radial system, the screen was placed around the screw so that the extrudates were ejected perpendicular to the motion of the screw. A die of 2 mm in diameter was used in this study to allow comparisons. The extruders' total open areas also were different. The screen thickness of the radial, dome, and axial systems presented 52.4, 22.7, and 15.5% open area and a 1-, 1.2-, and 2-mm screen thickness, respectively.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here